ライフサイエンスコーパス: obstructive

1 Use of inhalants for obstructive airway diseases (PR = 0.79; 95% CI = 0.74-0.

2 c syndrome-related conditions, inhalants for obstructive airway diseases and glucocorticoid use.

3 d natural history of imminent pediatric muco-obstructive airway diseases such as cystic fibrosis rema

4 [12%] deaths), mainly pneumonia and chronic obstructive airways disease.

5 cally decreased in the tubulointerstitium in obstructive and aristolochic acid nephropathy, which cor

6 ac medications, and alternate apnea type for obstructive and central apnea.

7 cardiology clinics have a high prevalence of obstructive and central sleep apnea associated with Chey

8 7.0%), whereas the prevalence of predominant obstructive apneas (OA) was 12.8% (AHI >/=5 events/h wit

9 iography, performed in 1126 patients, showed obstructive CAD (>/=50% stenosis) in 814 patients and se

10 ne or less than 50% stenosis, 29 (33.3%) had obstructive CAD (>/=50% stenosis), 7 (8%) with single-ve

11 used to determine the presence or absence of obstructive CAD (>/=50% stenosis).

12 diovascular deaths occurred in women without obstructive CAD (<50% stenosis).

13 as men showed a higher frequency of severely obstructive CAD (P=0.002).

14 Prevalence of obstructive CAD and myocardial ischemia was low (11.9% v

15 iography had a significantly lower burden of obstructive CAD in comparison with men but were not prot

16 The relationship between age, sex, and obstructive CAD status and outcomes post-MI has not been

17 ths in this cohort occurred in women without obstructive CAD, a condition often considered benign and

18 Independent predictors of mortality were obstructive CAD, age, baseline systolic blood pressure,

19 up was comparable to angiogram group without obstructive CAD, and both control group I and control gr

20 Impaired CFR, particularly absent severely obstructive CAD, may represent a novel target for CVD ri

21 have stable chest pain with a low burden of obstructive CAD, myocardial ischemia, and events.

22 ide treatment guidance for the group without obstructive CAD.

23 ype negative), 10 patients with hypertrophic obstructive cardiomyopathy (HOCM), 10 patients with aort

24 Hypertrophic obstructive cardiomyopathy is an inherited myocardial di

25 arium swallow, and oesophageal manometry, no obstructive cause may be found.

26 Biliary atresia (BA) is a neonatal obstructive cholangiopathy that progresses to end-stage

27 ecific to those rotavirus strains that cause obstructive cholangiopathy.

28 and managing patients with ischemia with no obstructive coronary arteries and outlines knowledge gap

29 the syndrome of myocardial ischemia with no obstructive coronary arteries.

30 nts (mean age 51+/-8.8 years), 80 (6.5%) had obstructive coronary artery disease (>/=70% stenosis) an

31 Prevalence of obstructive coronary artery disease (1%-64%), ACS (1%-44

32 rates are higher for women than for men, yet obstructive coronary artery disease (CAD) is less preval

33 METHODS AND Obstructive coronary artery disease (CAD) was defined as

34 ain and intermediate pretest probability for obstructive coronary artery disease (CAD) were randomly

35 l test results, nor if such results indicate obstructive coronary artery disease (CAD).

36 d MINOCA has a better prognosis than MI with obstructive coronary artery disease (MI-CAD).

37 AC, but were found to be appropriate because obstructive coronary artery disease and ACS were more pr

38 gnetic resonance imaging, after exclusion of obstructive coronary artery disease by angiography.

39 Despite women having a lower burden of obstructive coronary artery disease compared with men, t

40 decision-making process of ACS patients with obstructive coronary artery disease is associated with a

41 d diagnostic yield to identify patients with obstructive coronary artery disease on subsequent invasi

42 ea) and intermediate pretest probability for obstructive coronary artery disease were randomized to F

43 puborectalis syndrome (PPS) in patients with obstructive defecation syndrome (ODS).

44 The prevalence of obstructive disease did not differ by HIV status.

45 Pulmonary arterial hypertension (PAH) is an obstructive disease of the precapillary pulmonary arteri

46 and investigation to allow the causes of non-obstructive dysphagia to be identified, including functi

47 HFpEF, in the absence of known history for obstructive epicardial coronary artery disease, is assoc

48 Patients with obstructive (>/=50% stenosis) left main (LM) coronary ar

49 y in the management of severely symptomatic, obstructive HCM patients.

50 Patients with a clinical diagnosis of obstructive HCM referred for surgical management of LVOT

51 nt mice rescued ectopic Ptch2 expression and obstructive hydronephrosis.

52 s of pulmonary hypertension in patients with obstructive hypertrophic cardiomyopathy and advanced hea

53 he management of drug-refractory symptoms of obstructive hypertrophic cardiomyopathy has long been de

54 Pulmonary hypertension was common in obstructive hypertrophic cardiomyopathy patients with ad

55 l septal ablation (ASA) for the treatment of obstructive hypertrophic cardiomyopathy, the arrhythmoge

56 utrophil elastase (NE) expression induced by obstructive injury.

57 Although rare, obstructive jaundice due to external bile duct compressi

58 has excellent accuracy in the evaluation of obstructive jaundice with regards to the level and cause

59 nd out the role of MDCT in the evaluation of obstructive jaundice with respect to the cause and level

60 nted to an outside hospital with symptoms of obstructive jaundice, including abdominal pain and yello

61 provides temporary relief for patients with obstructive jaundice.

62 d from 50 patients with clinically suspected obstructive jaundice.

63 Using a functional obstructive labeling approach, we show that activation o

64 Obstructive labeling of BAK beyond the BH3 domain and hy

65 After excluding those with obstructive LM CAD, 5166 patients were categorized as ha

66 y duration, 5 yr) and the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study (n = 1,551 subj

67 art disease or stage 2 Global initiative for Obstructive Lung Disease (GOLD) COPD who had been clinic

68 terised by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric category (1-

69 f obstructive lung disease, the phenotype of obstructive lung disease associated with work-related or

70 Based on Global Initiative for Chronic Obstructive Lung Disease guidelines, 461 patients (17.6%

71 by using the composite Global Initiative for Obstructive Lung Disease scale (P < .0001).

72 ants (11%) met Global Initiative for Chronic Obstructive Lung Disease spirometric criteria for lung-f

73 test effect in Global Initiative for Chronic Obstructive Lung Disease stage 1, where each exacerbatio

74 re observed in Global Initiative for Chronic Obstructive Lung Disease stage 2 and 3 subjects.

75 nts with COPD (Global Initiative for Chronic Obstructive Lung Disease stage II-IV) underwent hyperpol

76 cise index, or Global Initiative for Chronic Obstructive Lung Disease stage.

77 ld smoking may predispose neonates with muco-obstructive lung disease to bacterial exacerbations.

78 ] years, GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages I-IV: 9.4, 42.5, 37.5,

79 Endpoints), and GenKOLS (Genetics of Chronic Obstructive Lung Disease) studies were analyzed.

80 pulmonary research and clinical practice in obstructive lung disease, and drug discovery platforms w

81 es contribute to a significant proportion of obstructive lung disease, the phenotype of obstructive l

82 outh demonstrated decreased reversibility of obstructive lung disease, which is atypical of asthma.

83 ) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by

84 disease (COPD) are highly prevalent chronic obstructive lung diseases with an associated high burden

85 Applications in patients with obstructive lung diseases, such as asthma and chronic ob

86 previously established mouse model of severe obstructive lung diseases, to produce lower-mortality bu

87 cessation of transport in persons with muco-obstructive lung diseases.

88 t 'INITIATIVES BronchoPneumopathie Chronique Obstructive' (n = 998 patients) were analyzed to assess

89 also reproduced experimentally the toxic and obstructive nature of vancomycin-associated cast nephrop

90 tive function in a mouse model of unilateral obstructive nephropathy, which cannot be diagnosed with

91 nt intracoronary multimodality imaging of an obstructive nonculprit lesion, before and after therapy.

92 ing optical coherence tomography (OCT) of an obstructive nonculprit lesion.

93 We assessed whether elevations in the obstructive or central sleep apnea index or the presence

94 P = .020) overall and among just those with obstructive PFT results (adjusted PR, 0.46; P = .016).

95 BECs from children with asthma and with obstructive physiology exhibit greater expression of typ

96 (27.4%), diabetes mellitus (29.5%), chronic obstructive pulmonary disease (16.0%), and a mean logist

97 tia with frailty (29%), frailty with chronic obstructive pulmonary disease (25%), and frailty with di

98 c surgery (18% versus 12%, P<0.001), chronic obstructive pulmonary disease (5% versus 3%, P=0.004), u

99 adults with asthma were as follows: chronic obstructive pulmonary disease (COPD) (13.4% vs 3.1%), de

100 Chronic obstructive pulmonary disease (COPD) affects over 65 mil

101 expression in lungs of patients with chronic obstructive pulmonary disease (COPD) and asthma compared

102 To determine how chronic obstructive pulmonary disease (COPD) and mechanical vent

103 Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalen

104 nist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.

105 al lung ventilation in patients with chronic obstructive pulmonary disease (COPD) by using free-breat

106 Chronic obstructive pulmonary disease (COPD) comprises chronic b

107 susceptible regions have effects on chronic obstructive pulmonary disease (COPD) development, while

108 ng noninvasive ventilation (NIV) for chronic obstructive pulmonary disease (COPD) exacerbations, heli

109 RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) frequently have alb

110 other respiratory conditions such as chronic obstructive pulmonary disease (COPD) has not been invest

111 to inhaled therapy by patients with chronic obstructive pulmonary disease (COPD) has not been report

112 f eosinophils in blood and sputum in chronic obstructive pulmonary disease (COPD) have been associate

113 People with advanced chronic obstructive pulmonary disease (COPD) have distressing ph

114 n smoking behavior and lung function/chronic obstructive pulmonary disease (COPD) have not been syste

115 ntified as a susceptibility gene for chronic obstructive pulmonary disease (COPD) in genome-wide asso

116 ciation between childhood asthma and chronic obstructive pulmonary disease (COPD) in later life has b

117 The burden of chronic obstructive pulmonary disease (COPD) in the USA continue

118 RATIONALE: Acute exacerbations of chronic obstructive pulmonary disease (COPD) increase the risk o

119 RATIONALE: Chronic obstructive pulmonary disease (COPD) is a chronic, progr

120 Chronic obstructive pulmonary disease (COPD) is a complex and he

121 Chronic obstructive pulmonary disease (COPD) is a leading cause

122 Chronic obstructive pulmonary disease (COPD) is a leading cause

123 Chronic obstructive pulmonary disease (COPD) is a risk factor fo

124 Chronic obstructive pulmonary disease (COPD) is associated with

125 RATIONALE: Chronic obstructive pulmonary disease (COPD) is characterized by

126 Chronic obstructive pulmonary disease (COPD) is characterized by

127 Chronic obstructive pulmonary disease (COPD) is characterized by

128 RATIONALE: The prevalence of chronic obstructive pulmonary disease (COPD) is increasing faste

129 RATIONALE: The burden of chronic obstructive pulmonary disease (COPD) is increasing, yet

130 RATIONALE: Chronic obstructive pulmonary disease (COPD) is often unrecogniz

131 Chronic obstructive pulmonary disease (COPD) is regarded as a di

132 clinical relevance in patients with chronic obstructive pulmonary disease (COPD) is scarce.

133 With increasingly aging populations, chronic obstructive pulmonary disease (COPD) is the fourth leadi

134 del of cigarette smoke (CS) -induced chronic obstructive pulmonary disease (COPD) is the primary test

135 The role of fibrocytes in chronic obstructive pulmonary disease (COPD) is unknown.

136 Some of the Chronic Obstructive Pulmonary Disease (COPD) patients engaged in

137 al infection; however, in asthma and chronic obstructive pulmonary disease (COPD) patients, this viru

138 y exacerbation risk in patients with chronic obstructive pulmonary disease (COPD) rely on a history o

139 erging models for predicting risk of chronic obstructive pulmonary disease (COPD) require external va

140 Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute non

141 s known about the natural history of chronic obstructive pulmonary disease (COPD) that has developed

142 nsplantation (n = 11) and those with chronic obstructive pulmonary disease (COPD) who were undergoing

143 Patients with chronic obstructive pulmonary disease (COPD) with an eosinophili

144 armacological treatment decisions in chronic obstructive pulmonary disease (COPD), a personalized app

145 ent (52 of 78) of patients exhibited chronic obstructive pulmonary disease (COPD), although only 19 h

146 dental cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), and lung-cancer mo

147 in identifying subphenotypes within chronic obstructive pulmonary disease (COPD), asthma, and other

148 erved in the airway in patients with chronic obstructive pulmonary disease (COPD), but their clinical

149 RATIONALE: Chronic obstructive pulmonary disease (COPD), in particular emph

150 RATIONALE: In chronic obstructive pulmonary disease (COPD), the benefits of pu

151 older individuals and in those with chronic obstructive pulmonary disease (COPD), whereas shorter-te

152 of a 63-year-old man suffering from chronic obstructive pulmonary disease (COPD), who presented with

153 ied by the tumor-enhancing effect of chronic obstructive pulmonary disease (COPD)-type airway inflamm

154 teroid efficacy in the management of chronic obstructive pulmonary disease (COPD).

155 ae (NTHi) persists in the airways in chronic obstructive pulmonary disease (COPD).

156 activity is a key therapeutic aim in chronic obstructive pulmonary disease (COPD).

157 ons for select conditions, including chronic obstructive pulmonary disease (COPD).

158 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

159 a whole-lung basis in patients with chronic obstructive pulmonary disease (COPD).

160 ors and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD).

161 e predicted of FEV1 in patients with chronic obstructive pulmonary disease (COPD).

162 own to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD).

163 ors and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD).

164 cation of gene expression studies in chronic obstructive pulmonary disease (COPD).

165 associated with worse outcomes than chronic obstructive pulmonary disease (COPD).

166 lung structure in conditions such as chronic obstructive pulmonary disease (COPD).

167 RNAs in lung tissue of patients with chronic obstructive pulmonary disease (COPD).

168 mation and airway wall remodeling in chronic obstructive pulmonary disease (COPD).

169 (HHIP) are robustly associated with chronic obstructive pulmonary disease (COPD).

170 impairment that was consistent with chronic obstructive pulmonary disease (COPD); these participants

171 ith comorbid allergy (P = 0.045) and chronic obstructive pulmonary disease (COPD; P = 0.015).

172 ckage to the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) study to examin

173 y (p = 0.88), 30-day readmission for chronic obstructive pulmonary disease (p = 0.83), or hospital le

174 ts [5%]), pneumonia (nine [5%]), and chronic obstructive pulmonary disease (six [3%]).

175 he COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease [COPD]; non-Hispanic white

176 Twenty-two ex-smokers with combined chronic obstructive pulmonary disease and heart failure with red

177 finding in patients with coexistent chronic obstructive pulmonary disease and heart failure.

178 d in the quadriceps of patients with chronic obstructive pulmonary disease and intensive care unit-ac

179 major site of airflow obstruction in chronic obstructive pulmonary disease and may precede emphysema

180 , drug use disorders, and history of chronic obstructive pulmonary disease and occupational lung dise

181 evelops in many patients with chronic severe obstructive pulmonary disease and other advanced lung di

182 primarily in central Appalachia for chronic obstructive pulmonary disease and pneumoconiosis; widely

183 ortion (25% to 45%) of patients with chronic obstructive pulmonary disease are never-smokers, most ge

184 3p/5p were elevated in patients with chronic obstructive pulmonary disease but more markedly in patie

185 eve better outcomes of patients with chronic obstructive pulmonary disease exacerbation treated with

186 utcomes among patients with an acute chronic obstructive pulmonary disease exacerbation.

187 RATIONALE: Chronic obstructive pulmonary disease exacerbations are associat

188 NALE: Genetic association studies in chronic obstructive pulmonary disease have primarily tested for

189 6 million to 6.8 million) DALYs from chronic obstructive pulmonary disease in 2015.

190 ed self-management for patients with chronic obstructive pulmonary disease in primary care.

191 BACKGROUND AND Chronic obstructive pulmonary disease is increasing in prevalenc

192 nity settings to limit the impact of chronic obstructive pulmonary disease on everyday life of indivi

193 sively increased from mild to severe chronic obstructive pulmonary disease severity.

194 ily mortality due to respiratory and chronic obstructive pulmonary disease specifically were positive

195 d for rare variation contributing to chronic obstructive pulmonary disease susceptibility.

196 tional study of 13,893 patients with chronic obstructive pulmonary disease treated with noninvasive v

197 diseases, chronic kidney disease and chronic obstructive pulmonary disease were important risk factor

198 on and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy

199 eart failure, stroke, pneumonia, and chronic obstructive pulmonary disease) and a surgical diagnosis

200 s index, chronic kidney disease, and chronic obstructive pulmonary disease).

201 of heart failure, moderate-to-severe chronic obstructive pulmonary disease, airway patency problems,

202 en, sodium, cerebrovascular disease, chronic obstructive pulmonary disease, and hemoglobin, was a pow

203 acute respiratory distress syndrome, chronic obstructive pulmonary disease, and interstitial lung dis

204 dy mass index, polyvascular disease, chronic obstructive pulmonary disease, and malignancy.

205 0-mug/m3 increase) with respiratory, chronic obstructive pulmonary disease, and pneumonia mortality,

206 tory lung diseases including asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis.

207 Older participants, those with chronic obstructive pulmonary disease, and those with more than

208 morbidities including renal disease, chronic obstructive pulmonary disease, atrial fibrillation, hear

209 lesterol, stroke, arthritis, asthma, chronic obstructive pulmonary disease, cancer, weak/failing kidn

210 astatin group (atrial septal defect, chronic obstructive pulmonary disease, chest pain, diverticuliti

211 line age, body mass index, diabetes, chronic obstructive pulmonary disease, coronary artery disease,

212 onary artery disease, heart failure, chronic obstructive pulmonary disease, diabetes mellitus, nitrat

213 hnicity, education, body mass index, chronic obstructive pulmonary disease, emphysema, personal histo

214 nic lung diseases such as asthma and chronic obstructive pulmonary disease, estimating physiologic im

215 stantial proportion of patients with chronic obstructive pulmonary disease, even after smoking cessat

216 s for asthma in children and adults, chronic obstructive pulmonary disease, hypertension, diabetes, o

217 ve lung diseases, such as asthma and chronic obstructive pulmonary disease, include not only diagnost

218 ffecting the lung, including asthma, chronic obstructive pulmonary disease, infections, and cancer.

219 rt disease, cerebrovascular disease, chronic obstructive pulmonary disease, lung cancer, and lower re

220 nflammatory disease models including chronic obstructive pulmonary disease, multiple sclerosis, and s

221 derately impaired ejection fraction, chronic obstructive pulmonary disease, peripheral vascular disea

222 comitant IL-1beta responses occur in chronic obstructive pulmonary disease, respiratory infections, a

223 Patients with cystic fibrosis, chronic obstructive pulmonary disease, severe asthma, pre-existi

224 r exercise ventilatory efficiency in chronic obstructive pulmonary disease-heart failure overlap.

225 re of several lung pathologies, e.g. chronic obstructive pulmonary disease.

226 goals of treatment for patients with chronic obstructive pulmonary disease.

227 rbations of both cystic fibrosis and chronic obstructive pulmonary disease.

228 ial aggregation, and associated with chronic obstructive pulmonary disease.

229 le effect modification by asthma and chronic obstructive pulmonary disease.

230 nostic and therapeutic approaches in chronic obstructive pulmonary disease.

231 patients with acute exacerbation of chronic obstructive pulmonary disease.

232 en demonstrated yet in patients with chronic obstructive pulmonary disease.

233 g, which is the main risk factor for chronic obstructive pulmonary disease.

234 o exercise training in patients with chronic obstructive pulmonary disease.

235 , including cystic fibrosis (CF) and chronic obstructive pulmonary disease.

236 his might indicate an early stage of chronic obstructive pulmonary disease.

237 ergic receptor agonist used to treat chronic obstructive pulmonary disease.

238 ce of other airway diseases, such as chronic obstructive pulmonary disease.

239 arthritis; OR 1.71; asthma: OR 1.56; chronic obstructive pulmonary disease: OR 1.65; cancer: OR 1.23;

240 racteristics (older age, female sex, chronic obstructive pulmonary disease; P<0.05 for all), periproc

241 ammatory diseases such as asthma and chronic obstructive pulmonary diseases (COPD) affect more than o

242 r are necessary parameters to detect chronic obstructive pulmonary diseases (COPDs) such as asthma, b

243 and 132 HEU participants) were classified as obstructive, restrictive, or normal, and reversibility w

244 t), body mass index >/=25kg/m(2) (+1 point), obstructive sleep apnea (+1 point), gastroesophageal ref

245 Obstructive sleep apnea (OSA) affects 8-10% of the popul

246 ssible association between periodontitis and obstructive sleep apnea (OSA) has been suggested.

247 An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and

248 data from the 1990s, estimated prevalence of obstructive sleep apnea (OSA) in the United States is 10

249 Obstructive sleep apnea (OSA) is a worldwide disease who

250 Obstructive sleep apnea (OSA) is associated with atrial

251 RATIONALE: Obstructive sleep apnea (OSA) is associated with several

252 Obstructive sleep apnea (OSA) is characterized by recurr

253 oratory polysomnography (PSG) for diagnosing obstructive sleep apnea (OSA) is unclear.

254 ationship between floppy eyelid syndrome and obstructive sleep apnea (OSA), the diagnostic criteria o

255 ay represent a critical pathology underlying obstructive sleep apnea (OSA).

256 retinal vascular caliber and the severity of obstructive sleep apnea (OSA).

257 s positive airway pressure for patients with obstructive sleep apnea (OSA).

258 adverse health outcomes are associated with obstructive sleep apnea (OSA).

259 n human subjects with high and low risks for obstructive sleep apnea (OSA).

260 ascular events, is linked to the severity of obstructive sleep apnea (OSA).

261 ificantly less improvement in ACT scores was obstructive sleep apnea (P = 0.016).

262 hanistic and empirical bases for considering obstructive sleep apnea and central sleep apnea associat

263 RATIONALE: Obstructive sleep apnea causes intermittent hypoxemia, h

264 cators of obstruction sites in patients with obstructive sleep apnea hypopnea syndrome (OSAHS).

265 Obstructive sleep apnea is a common disorder associated

266 Epidemiological research indicates that obstructive sleep apnea is associated with increases in

267 n gray matter characteristics and markers of obstructive sleep apnea severity (hypoxemia, respiratory

268 To investigate whether markers of obstructive sleep apnea severity are associated with gra

269 Obstructive sleep apnea syndrome (OSAS) is associated wi

270 e (CPAP) in asthma patients with concomitant obstructive sleep apnea syndrome (OSAS) seems to have a

271 ucture, hippocampus-dependent cognition, and obstructive sleep apnea syndrome (OSAS).

272 Obstructive sleep apnea syndrome is a highly prevalent d

273 ncluded obesity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of res

274 essure in asthmatics with moderate to severe obstructive sleep apnea syndrome.

275 Prevalence of severe obstructive sleep apnea was 51% (95% confidence interval

276 ll trials provide evidence that treatment of obstructive sleep apnea with continuous positive airway

277 icularly in children with moderate to severe obstructive sleep apnea, and also that even snoring alon

278 estyle, smoking, obesity, diabetes mellitus, obstructive sleep apnea, and elevated blood pressure pre

279 management of more symptomatic patients with obstructive sleep apnea, but its effectiveness has not b

280 patient-level factors that included obesity, obstructive sleep apnea, higher comorbidity, and use of

281 tal health and psychological issues, asthma, obstructive sleep apnea, orthopedic problems, and advers

282 ovascular and cognitive consequences seen in obstructive sleep apnea.

283 isms attributed to a presymptomatic stage of obstructive sleep apnea.

284 ationale for a new pharmacologic therapy for obstructive sleep apnea.

285 eeSurfer revealed increased gray matter with obstructive sleep apnea.

286 mulating blood O2 saturation profiles during obstructive sleep apnoea (OSA), have been shown to exhib

287 mulating blood O2 saturation profiles during obstructive sleep apnoea (OSA), have been shown to exhib

288 ociated with a relatively high prevalence of obstructive sleep apnoea (OSA).

289 ociated with a relatively high prevalence of obstructive sleep apnoea (OSA).

290 active at rest, e.g. essential hypertension, obstructive sleep apnoea and heart failure.

291 ardiovascular related pathologies, including obstructive sleep apnoea, heart failure and diabetes.

292 nic rhinosinusitis, gastroesophageal reflux, obstructive sleep apnoea, vocal cord dysfunction, obesit

293 rfusion deficits and detection of per-vessel obstructive stenosis by invasive coronary angiography we

294 For regional detection of obstructive stenosis, ischemic total perfusion deficit a

295 Multi-Center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesi

296 CTD) case-parent trios, 317 left ventricular obstructive tract defect (LVOTD) case-parent trios, and

297 s renal biopsy specimen, we ascertained that obstructive tubular casts composed of noncrystal nanosph

298 Analysis of obstructive ureteric tissue resected from children with

299 y Network criteria), exclusion criteria were obstructive uropathy, urothelial carcinoma, and metastat

300 Pulmonary arterial hypertension (PAH) is an obstructive vasculopathy characterized by excessive pulm